FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163309330> ?p ?o ?g. }

• W3163309330 abstract "Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of fibrillar collagens in the alveolar space resulting in reduced pulmonary function and a high mortality rate. Biomarkers measuring the turnover of type I and III collagen could provide valuable information for prognosis and treatment decisions in IPF.Serological biomarkers reflecting the formation of type III collagen (PRO-C3) and degradation of type I (C1M) and III collagen (C3M) were evaluated in a real-world cohort of 178 newly diagnosed IPF patients. Blood samples and clinical data were collected at baseline, six, and 12 months. Baseline and longitudinal biomarker levels were related to disease progression of IPF (defined as ≥ 5% decline in forced vital capacity (FVC) and/or ≥ 10% decline in diffusing capacity for carbon monoxide (DLco) and/or all-cause mortality at 12 months). Furthermore, we analysed differences in percentage change of biomarker levels from baseline between patients receiving antifibrotic treatment or not.Increased baseline levels of type I and III collagen turnover biomarkers were associated with a greater risk of disease progression within 12 months compared to patients with a low baseline type I and III collagen turnover. Patients with progressive disease had higher serum levels of C1M (P = 0.038) and PRO-C3 (P = 0.0022) compared to those with stable disease over one year. There were no differences in biomarker levels between patients receiving pirfenidone, nintedanib, or no antifibrotics.Baseline levels of type I and III collagen turnover were associated with disease progression within 12 months in a real-world cohort of IPF patients. Longitudinal biomarker levels of type I and III collagen turnover were related to progressive disease. Moreover, antifibrotic therapy did not affect type I and III collagen turnover biomarkers in these patients. PRO-C3 and C1M may be potential biomarkers for a progressive disease behavior in IPF." @default.
• W3163309330 created "2021-05-24" @default.
• W3163309330 creator A5013500619 @default.
• W3163309330 creator A5022871532 @default.
• W3163309330 creator A5024309558 @default.
• W3163309330 creator A5031089969 @default.
• W3163309330 creator A5054029103 @default.
• W3163309330 creator A5062465642 @default.
• W3163309330 creator A5076601121 @default.
• W3163309330 creator A5078364928 @default.
• W3163309330 creator A5084344695 @default.
• W3163309330 date "2021-07-15" @default.
• W3163309330 modified "2023-09-27" @default.
• W3163309330 title "Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis" @default.
• W3163309330 cites W1971485286 @default.
• W3163309330 cites W1982315942 @default.
• W3163309330 cites W2002587076 @default.
• W3163309330 cites W2046246972 @default.
• W3163309330 cites W2056875960 @default.
• W3163309330 cites W2058234974 @default.
• W3163309330 cites W2065988977 @default.
• W3163309330 cites W2071610384 @default.
• W3163309330 cites W2080677332 @default.
• W3163309330 cites W2117488044 @default.
• W3163309330 cites W2125013258 @default.
• W3163309330 cites W2126011452 @default.
• W3163309330 cites W2138871107 @default.
• W3163309330 cites W2150969530 @default.
• W3163309330 cites W2167383172 @default.
• W3163309330 cites W2168666423 @default.
• W3163309330 cites W2289682006 @default.
• W3163309330 cites W2604367936 @default.
• W3163309330 cites W2799479598 @default.
• W3163309330 cites W2810579324 @default.
• W3163309330 cites W2889197569 @default.
• W3163309330 cites W2914542634 @default.
• W3163309330 cites W2947690783 @default.
• W3163309330 cites W2956839011 @default.
• W3163309330 cites W2959512696 @default.
• W3163309330 cites W2970117113 @default.
• W3163309330 cites W2999705230 @default.
• W3163309330 cites W3084144173 @default.
• W3163309330 cites W3147853291 @default.
• W3163309330 doi "https://doi.org/10.1186/s12931-021-01801-0" @default.
• W3163309330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8281632" @default.
• W3163309330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34261485" @default.
• W3163309330 hasPublicationYear "2021" @default.
• W3163309330 type Work @default.
• W3163309330 sameAs 3163309330 @default.
• W3163309330 citedByCount "15" @default.
• W3163309330 countsByYear W31633093302022 @default.
• W3163309330 countsByYear W31633093302023 @default.
• W3163309330 crossrefType "journal-article" @default.
• W3163309330 hasAuthorship W3163309330A5013500619 @default.
• W3163309330 hasAuthorship W3163309330A5022871532 @default.
• W3163309330 hasAuthorship W3163309330A5024309558 @default.
• W3163309330 hasAuthorship W3163309330A5031089969 @default.
• W3163309330 hasAuthorship W3163309330A5054029103 @default.
• W3163309330 hasAuthorship W3163309330A5062465642 @default.
• W3163309330 hasAuthorship W3163309330A5076601121 @default.
• W3163309330 hasAuthorship W3163309330A5078364928 @default.
• W3163309330 hasAuthorship W3163309330A5084344695 @default.
• W3163309330 hasBestOaLocation W31633093301 @default.
• W3163309330 hasConcept C126322002 @default.
• W3163309330 hasConcept C16020263 @default.
• W3163309330 hasConcept C165637977 @default.
• W3163309330 hasConcept C185592680 @default.
• W3163309330 hasConcept C2777714996 @default.
• W3163309330 hasConcept C2778341716 @default.
• W3163309330 hasConcept C2779832356 @default.
• W3163309330 hasConcept C2780559512 @default.
• W3163309330 hasConcept C2781197716 @default.
• W3163309330 hasConcept C2781244666 @default.
• W3163309330 hasConcept C3018587741 @default.
• W3163309330 hasConcept C55493867 @default.
• W3163309330 hasConcept C55520419 @default.
• W3163309330 hasConcept C71924100 @default.
• W3163309330 hasConcept C72563966 @default.
• W3163309330 hasConcept C75603125 @default.
• W3163309330 hasConcept C90924648 @default.
• W3163309330 hasConceptScore W3163309330C126322002 @default.
• W3163309330 hasConceptScore W3163309330C16020263 @default.
• W3163309330 hasConceptScore W3163309330C165637977 @default.
• W3163309330 hasConceptScore W3163309330C185592680 @default.
• W3163309330 hasConceptScore W3163309330C2777714996 @default.
• W3163309330 hasConceptScore W3163309330C2778341716 @default.
• W3163309330 hasConceptScore W3163309330C2779832356 @default.
• W3163309330 hasConceptScore W3163309330C2780559512 @default.
• W3163309330 hasConceptScore W3163309330C2781197716 @default.
• W3163309330 hasConceptScore W3163309330C2781244666 @default.
• W3163309330 hasConceptScore W3163309330C3018587741 @default.
• W3163309330 hasConceptScore W3163309330C55493867 @default.
• W3163309330 hasConceptScore W3163309330C55520419 @default.
• W3163309330 hasConceptScore W3163309330C71924100 @default.
• W3163309330 hasConceptScore W3163309330C72563966 @default.
• W3163309330 hasConceptScore W3163309330C75603125 @default.
• W3163309330 hasConceptScore W3163309330C90924648 @default.
• W3163309330 hasFunder F4320309432 @default.
• W3163309330 hasFunder F4320324424 @default.
• W3163309330 hasFunder F4320334770 @default.

• next